Siltuximab: Difference between revisions

Jump to navigation Jump to search
(Created page with "{{DrugProjectFormSinglePage |authorTag={{AP}} |genericName=Siltuximab |aOrAn=a |drugClass=monoclonal antibody |indicationType=treatment |indication=patients with multi c...")
 
No edit summary
Line 5: Line 5:
|drugClass=[[monoclonal antibody]]
|drugClass=[[monoclonal antibody]]
|indicationType=treatment
|indicationType=treatment
|indication=patients with [[multi centric Castleman's disease]] ([[MCD]]) who are [[human immunodeficiency virus]] ([[HIV]]) negative and [[human herpesvirus-8]] ([[HHV-8]]) negative.
|indication=patients with [[multi centric Castleman's disease]] ([[MCD]]) who are [[human immunodeficiency virus]] ([[HIV]]) negative and [[human herpesvirus-8]] ([[HHV-8]]) negative. SYLVANT was not studied in patients with MCD who are [[HIV]] positive or [[HHV-8]] positive because SYLVANT did not bind to virally produced [[IL-6]] in a nonclinical study
<br>
 
=====Limitation of Use=====
SYLVANT was not studied in patients with MCD who are [[HIV]] positive or [[HHV-8]] positive because SYLVANT did not bind to virally produced [[IL-6]] in a nonclinical study
|adverseReactions=[[pruritus]], [[increased weight]], [[rash]], [[hyperuricemia]], and [[upper respiratory tract infection]]
|adverseReactions=[[pruritus]], [[increased weight]], [[rash]], [[hyperuricemia]], and [[upper respiratory tract infection]]
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b>
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b>

Revision as of 13:53, 16 February 2015

Siltuximab
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alberto Plate [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Siltuximab is a monoclonal antibody that is FDA approved for the treatment of patients with multi centric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. SYLVANT was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANT did not bind to virally produced IL-6 in a nonclinical study. Common adverse reactions include pruritus, increased weight, rash, hyperuricemia, and upper respiratory tract infection.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

There is limited information regarding Siltuximab FDA-Labeled Indications and Dosage (Adult) in the drug label.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Siltuximab in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Siltuximab in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Siltuximab FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Siltuximab in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Siltuximab in pediatric patients.

Contraindications

  • Severe hypersensitivity reaction to siltuximab or any of the excipients in SYLVANT.

Warnings

Concurrent Active Severe Infections

  • Do not administer SYLVANT to patients with severe infections until the infection resolves. SYLVANT may mask signs and symptoms of acute inflammation including suppression of fever and of acute phase reactants such as C-reactive protein (CRP). Monitor patients receiving SYLVANT closely for infections. Institute prompt anti-infective therapy and do not administer further SYLVANT until the infection resolves.

Vaccinations

  • Do not administer live vaccines to patients receiving SYLVANT because IL-6 inhibition may interfere with the normal immune response to new antigens.

Infusion Related Reactions and Hypersensitivity

  • Stop the infusion of SYLVANT if the patient develops signs of anaphylaxis. Discontinue further therapy with SYLVANT.
  • Stop the infusion if the patient develops a mild to moderate infusion reaction. If the reaction resolves, the SYLVANT infusion may be restarted at a lower infusion rate. Consider medication with antihistamines, acetaminophen, and corticosteroids. Discontinue SYLVANT if the patient does not tolerate the infusion following these interventions.
  • Administer SYLVANT in a setting that provides resuscitation equipment, medication, and personnel trained to provide resuscitation.

Gastrointestinal Perforation

  • Gastrointestinal perforation has been reported in clinical trials although not in MCD trials. Use with caution in patients who may be at increased risk for GI perforation. Promptly evaluate patients presenting with symptoms that may be associated or suggestive of GI perforation.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Siltuximab Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Siltuximab Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Siltuximab Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Siltuximab in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Siltuximab in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Siltuximab during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Siltuximab in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Siltuximab in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Siltuximab in geriatric settings.

Gender

There is no FDA guidance on the use of Siltuximab with respect to specific gender populations.

Race

There is no FDA guidance on the use of Siltuximab with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Siltuximab in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Siltuximab in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Siltuximab in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Siltuximab in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Siltuximab Administration in the drug label.

Monitoring

There is limited information regarding Siltuximab Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Siltuximab and IV administrations.

Overdosage

There is limited information regarding Siltuximab overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Siltuximab Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Siltuximab Mechanism of Action in the drug label.

Structure

There is limited information regarding Siltuximab Structure in the drug label.

Pharmacodynamics

There is limited information regarding Siltuximab Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Siltuximab Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Siltuximab Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Siltuximab Clinical Studies in the drug label.

How Supplied

There is limited information regarding Siltuximab How Supplied in the drug label.

Storage

There is limited information regarding Siltuximab Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Siltuximab |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Siltuximab |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Siltuximab Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Siltuximab interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Siltuximab Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Siltuximab Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.